{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:25:09Z","timestamp":1762917909372,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":1510,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008169","name":"Minneapolis Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008169","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["(P30DA040500)"],"award-info":[{"award-number":["(P30DA040500)"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1111\/ajt.15040","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T03:24:30Z","timestamp":1532921070000},"page":"2483-2495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation"],"prefix":"10.1016","volume":"18","author":[{"given":"Brittany A.","family":"Shelton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deirdre","family":"Sawinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin P.","family":"Linas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Reese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaux","family":"Mustian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitch","family":"Hungerpiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhiannon D.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayme E.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1111\/ajt.15040_bib1","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"New England J Med."},{"issue":"10003","key":"10.1111\/ajt.15040_bib2","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet (London, England)."},{"issue":"16","key":"10.1111\/ajt.15040_bib3","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMe1401508","article-title":"Therapy for hepatitis C\u2014The costs of success","volume":"370","author":"Hoofnagle","year":"2014","journal-title":"N Eng J Med."},{"issue":"suppl 1","key":"10.1111\/ajt.15040_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ajt.14557","article-title":"OPTN\/SRTR 2016 annual data report: kidney","volume":"18","author":"Hart","year":"2018","journal-title":"Am J. Transplant."},{"issue":"5","key":"10.1111\/ajt.15040_bib5","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1681\/ASN.2006070736","article-title":"Hepatitis C virus and death risk in hemodialysis patients","volume":"18","author":"Kalantar-Zadeh","year":"2007","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"10.1111\/ajt.15040_bib6","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1097\/01.ASN.0000100127.54107.57","article-title":"Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"14","author":"Goodkin","year":"2003","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"10.1111\/ajt.15040_bib7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/ki.2015.74","article-title":"Superior outcomes in HIV-positive kidney transplant patients compared with HCV-infected or HIV\/HCV-coinfected recipients","volume":"88","author":"Sawinski","year":"2015","journal-title":"Kidney Int."},{"key":"10.1111\/ajt.15040_bib8","unstructured":"Axelrod DA, Schnitzler MA, Alhamad T, et al. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes [published online ahead of print 2018]. Am J Transplant."},{"issue":"5","key":"10.1111\/ajt.15040_bib9","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1600-6143.2010.03091.x","article-title":"Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients","volume":"10","author":"Kucirka","year":"2010","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15040_bib10","doi-asserted-by":"crossref","first-page":"e12829v","DOI":"10.1111\/tid.12829","article-title":"Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney","volume":"20","author":"Shelton","year":"2017","journal-title":"Transpl Infect Dis."},{"issue":"4","key":"10.1111\/ajt.15040_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMp1505074","article-title":"Transplanting hepatitis C-positive kidneys","volume":"373","author":"Reese","year":"2015","journal-title":"New Eng J Med."},{"issue":"10","key":"10.1111\/ajt.15040_bib12","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1111\/ajt.13971","article-title":"Improving organ utilization to help overcome the tragedies of the opioid epidemic","volume":"16","author":"Goldberg","year":"2016","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1111\/ajt.15040_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/TP.0b013e3181ac620b","article-title":"A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index","volume":"88","author":"Rao","year":"2009","journal-title":"Transplantation."},{"issue":"10","key":"10.1111\/ajt.15040_bib14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA."},{"issue":"9","key":"10.1111\/ajt.15040_bib15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/M14-1313","article-title":"The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection","volume":"162","author":"Linas","year":"2015","journal-title":"Ann Intern Med."},{"issue":"3","key":"10.1111\/ajt.15040_bib16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/QAD.0000000000000093","article-title":"The cost-effectiveness of improved hepatitis C virus therapies in HIV\/hepatitis C virus coinfected patients","volume":"28","author":"Linas","year":"2014","journal-title":"AIDS (London, England)."},{"issue":"6","key":"10.1111\/ajt.15040_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/M14-1336","article-title":"Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States","volume":"162","author":"Chhatwal","year":"2015","journal-title":"Ann Inter Med."},{"issue":"3","key":"10.1111\/ajt.15040_bib18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.28926","article-title":"Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list","volume":"65","author":"Chhatwal","year":"2017","journal-title":"Hepatology."},{"issue":"2","key":"10.1111\/ajt.15040_bib19","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology."},{"issue":"2","key":"10.1111\/ajt.15040_bib20","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/MCG.0b013e3181e12c09","article-title":"Direct economic burden of chronic hepatitis C virus in a United States managed care population","volume":"45","author":"Davis","year":"2011","journal-title":"J Clin Gastroenterol."},{"issue":"3","key":"10.1111\/ajt.15040_bib21","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","article-title":"Health-state utilities and quality of life in hepatitis C patients","volume":"98","author":"Chong","year":"2003","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"10.1111\/ajt.15040_bib22","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/gut.2005.064774","article-title":"Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C","volume":"55","author":"Grieve","year":"2006","journal-title":"Gut."},{"issue":"31","key":"10.1111\/ajt.15040_bib23","first-page":"1","article-title":"Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice","volume":"6","author":"Stein","year":"2002","journal-title":"Health Technol Assess (Winchester, England)."},{"issue":"5","key":"10.1111\/ajt.15040_bib24","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2009.31","article-title":"Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study","volume":"104","author":"Bruno","year":"2009","journal-title":"Am J Gastroenterol."},{"issue":"7","key":"10.1111\/ajt.15040_bib25","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/cid\/cir076","article-title":"Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more","volume":"52","author":"Pearlman","year":"2011","journal-title":"Clin Infect Dis."},{"issue":"24","key":"10.1111\/ajt.15040_bib26","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA."},{"issue":"6","key":"10.1111\/ajt.15040_bib27","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1681\/ASN.2010060668","article-title":"Effect of kidney transplantation on outcomes among patients with hepatitis C","volume":"22","author":"Roth","year":"2011","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"10.1111\/ajt.15040_bib28","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1046\/j.1600-6143.2004.00606.x","article-title":"The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients","volume":"4","author":"Abbott","year":"2004","journal-title":"Am J Transplant."},{"year":"2017","series-title":"USRDS annual data report: epidemiology of kidney disease in the United States 2017","key":"10.1111\/ajt.15040_bib29"},{"key":"10.1111\/ajt.15040_bib30","unstructured":"Recipients SRoT. Program-Specific Reports. 2018. https:\/\/www.srtr.org\/reports-tools\/program-specific-reports\/. Accessed May 10, 2018."},{"issue":"11","key":"10.1111\/ajt.15040_bib31","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1111\/ajt.14417","article-title":"Maximizing utilization of the donor pool by appropriate classification of hepatitis C antibody-positive donors","volume":"17","author":"Anesi","year":"2017","journal-title":"Am J Transplant."},{"issue":"8","key":"10.1111\/ajt.15040_bib32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med."},{"key":"10.1111\/ajt.15040_bib33","unstructured":"Kiberd B, Doucette K, Vinson A, Tennankore K. Hepatitis C virus infected kidney wait list patients: treat now or treat later? [published online ahead of print 2018] Am J Transplant."},{"issue":"6","key":"10.1111\/ajt.15040_bib34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int."},{"issue":"4","key":"10.1111\/ajt.15040_bib35","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.29258","article-title":"Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study","volume":"66","author":"Saxena","year":"2017","journal-title":"Hepatology (Baltimore, Md.)."},{"issue":"4","key":"10.1111\/ajt.15040_bib36","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1097\/TP.0000000000002099","article-title":"Race, risk, and willingness of end-stage renal disease patients without hepatitis C virus to accept an HCV-infected kidney transplant","volume":"102","author":"McCauley","year":"2018","journal-title":"Transplantation."},{"issue":"24","key":"10.1111\/ajt.15040_bib37","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of HCV-infected kidneys into uninfected recipients","volume":"376","author":"Goldberg","year":"2017","journal-title":"New Eng J Med."},{"issue":"6","key":"10.1111\/ajt.15040_bib38","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/1756283X16665254","article-title":"Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease","volume":"9","author":"Kohli","year":"2016","journal-title":"Therapeutic Adv Gastroenterol."},{"issue":"1","key":"10.1111\/ajt.15040_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00019053-200220010-00004","article-title":"Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation","volume":"20","author":"Hogan","year":"2002","journal-title":"Pharmaco Economics."},{"issue":"21","key":"10.1111\/ajt.15040_bib40","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1001\/archinte.164.21.2377","article-title":"Health values of patients with chronic hepatitis C infection","volume":"164","author":"Sherman","year":"2004","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1111\/ajt.15040_bib41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ctr.12073","article-title":"More donors or more delayed graft function? A cost-effectiveness analysis of DCD kidney transplantation","volume":"27","author":"Snyder","year":"2013","journal-title":"Clin Transplant."},{"issue":"9","key":"10.1111\/ajt.15040_bib42","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1093\/ndt\/gfq780","article-title":"Cost-effectiveness analysis of renal replacement therapy in Austria","volume":"26","author":"Haller","year":"2011","journal-title":"Nephrol Dial Transplant."},{"issue":"6","key":"10.1111\/ajt.15040_bib43","first-page":"1567","article-title":"Practice patterns, case mix, Medicare payment policy, and dialysis facility costs","volume":"33","author":"Hirth","year":"1999","journal-title":"Health Services Res."},{"issue":"10","key":"10.1111\/ajt.15040_bib44","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2165\/11588390-000000000-00000","article-title":"A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy","volume":"29","author":"Menzin","year":"2011","journal-title":"Pharmaco Econom."},{"issue":"3","key":"10.1111\/ajt.15040_bib45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1542-4758.2012.00676.x","article-title":"Effects of modality change on health-related quality of life","volume":"16","author":"Painter","year":"2012","journal-title":"Hemodial Int."},{"issue":"1","key":"10.1111\/ajt.15040_bib46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11136-012-0139-1","article-title":"Estimating utilities for chronic kidney disease, using SF-36 and SF-12-based measures: challenges in a population of veterans with diabetes","volume":"22","author":"Rajan","year":"2013","journal-title":"Quality Life."},{"issue":"1\u20132","key":"10.1111\/ajt.15040_bib47","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0041-1345(98)02013-2","article-title":"The cost-effectiveness of transplantation with expanded donor kidneys","volume":"31","author":"Whiting","year":"1999","journal-title":"Transplant Proc."},{"issue":"3","key":"10.1111\/ajt.15040_bib48","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1600-6143.2010.03425.x","article-title":"A description of the costs of living and standard criteria deceased donor kidney transplantation","volume":"11","author":"Barnieh","year":"2011","journal-title":"Am J Transplant."},{"issue":"21","key":"10.1111\/ajt.15040_bib49","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"New Eng J Med."},{"issue":"2","key":"10.1111\/ajt.15040_bib50","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/ALN.0b013e3181948a97","article-title":"Early packed red blood cell transfusion and acute respiratory distress syndrome after trauma","volume":"110","author":"Chaiwat","year":"2009","journal-title":"Anesthesiology."},{"issue":"3","key":"10.1111\/ajt.15040_bib51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1586\/erp.12.10","article-title":"Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C","volume":"12","author":"Gao","year":"2012","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.15040","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522097337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522097337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ajt.15040\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:22:31Z","timestamp":1761628951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522097337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1600613522097337"],"URL":"https:\/\/doi.org\/10.1111\/ajt.15040","relation":{},"ISSN":["1600-6135"],"issn-type":[{"type":"print","value":"1600-6135"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.15040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}